FOLH1 and prostate cancer: The presence of prostate specific membrane antigen (PSMA) expression in prostate cancer served as a basis for the idea of targeting these receptors for PET imaging using Ga-68 labelled PSMA and consequently treating with Lu-177 labelled PSMA (4,5).